Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
|Articles|August 10, 2021
Pharmacy Clinical Pearl of the Day: Long-acting vs Rapid-acting Insulin
Author(s)Saro Arakelians, PharmD
Depending on the patient needs, the prescriber can prescribe one or both types of insulin.
Advertisement
Clinical Pearl of the Day: Long-acting vs rapid-acting insulin
Explanation
- Long-acting insulins provides coverage for blood sugars for nearly the entire day.
- Rapid-acting insulins provide coverage when blood sugars spikes, as needed for patients with diabetes.
- Depending on the patient needs, the prescriber can prescribe either or both types of insulin for patients with diabetes.
Reference:
Advertisement
Related to this article
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5